Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Abstract

Plasma TREM2 is a plausible individual biomarker that can rule-in or rule-out the presence of NASH with high accuracy and thus has the potential to reduce the need for liver biopsies and to identify patients who are eligible for clinical trials in NASH.